INVESTORS

​

Market & Commercialization Strategy

Time is the biggest enemy of the pharmaceutical industry. It takes them 7-10 years to develop a product that is patented and FDA-approved. Our marketing strategy is focused on saving time and ease of use. First, the Proteometer not only saves hours and days – it also has better accuracy. Secondly, it is a “plug and play” consumable that utilizes existing tools and software already owned and used daily in all stages of the pharmaceutical development process. The go-to-market strategy will utilize major instrument and distributor channels that can sell more of their products with our technology. All manufacturing will be completed at GMP and ISO-validated suppliers to complement our similar assembly strategy. Combined, this focus will ensure way-above-average profits and an expeditious expansion into the market.

​

Technical & Competitive Advantage

The utilization of our patented nanotechnology is not available from any other source. To ease its use, the Proteometer (a.k.a. Proteoform Meter) has been tested and approved for use by 4 of the top 5 instrument companies in the world. Then its utility was confirmed in pilots at multiple major (Top 10) pharmaceutical companies. Two of them (Pfizer and J&J) then published peer-reviewed articles and presentations on the Proteometer

​

Regulatory Strategy & Intellectual Property

The Proteometer is first being adopted in pharma discovery, clone selection, and process R&D departments that do not have regulatory restrictions. If it is utilized in manufacturing, it will be part of the pharma company FDA submittal. As >90% of the target instruments are outside of manufacturing, regulatory approval is not a major part of our IP Go-to-Market strategy. Our IP includes multiple methods and concept of matter patents which combine to create a protective mote from outside duplication. We currently have additional patents pending with similar strategies.